Cabergoline
SIGMA/C0246 - ≥98% (HPLC)
Synonym: 1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea; 1-
CAS Number: 81409-90-7
Empirical Formula (Hill Notation): C26H37N5O2
Molecular Weight: 451.60
MDL Number: MFCD00867887
Linear Formula: C26H37N5O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C26H37N5O2/c1-5-11-30- |
| InChI key | KORNTPPJEAJQIU-KJXAQDMKSA |
| optical activity | [α]/D −63 to −74°, c = 0.5 in dichloromethane |
| originator | Johnson & Johnson |
| Quality Level | 100  |
| SMILES string | CCNC(=O)N(CCCN(C)C)C(=O)[ |
| solubility | DMSO: ≥10 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas). |
| Biochem/physiol Actions: | Dopamine D2-receptor agonist; Prolactin inhibitor; Antiparkinsonian |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |